Oncolytic Virus-Based Therapies for Neurological Disorders

The present invention expands the application of oncolytic viruses to neurological disorders, offering novel therapeutic approaches for treating conditions such as glioblastoma, Parkinson's disease, and spinal cord injuries.

While oncolytic viruses have shown promise in cancer treatment, their potential in addressing neurological disorders remains largely unexplored. The original patent's oncolytic virus, with its improved safety and anticancer effect, provides a foundation for exploring new applications in the field of neurology. However, the original patent's limitations in terms of targeted delivery and combination therapies for neurological disorders necessitate the development of new approaches.

The inventive concept involves the use of the recombinant oncolytic virus of claim 1 in treating neurological disorders. This includes methods for direct administration of the virus to the central nervous system, systems for targeted delivery to specific regions of the brain or spinal cord, and pharmaceutical compositions combining the virus with neural stem cells or stem cell therapies. The oncolytic virus's ability to selectively target and destroy cancer cells is leveraged to address the complex pathologies of neurological disorders.

The new claims introduce novel applications of the oncolytic virus in neurological disorders, which were not anticipated by the original patent. The inventive step lies in the recognition of the virus's potential in treating conditions beyond cancer and the development of targeted delivery systems and combination therapies to address the unique challenges of neurological disorders.

Alternative embodiments may include the use of different viral vectors, varying dosing regimens, or combination therapies with other neurologically active compounds. Variations may also involve adapting the delivery systems for use in different animal models or human clinical trials.

The inventive concept has significant commercial potential in the neurology market, with potential applications in treating glioblastoma, Parkinson's disease, spinal cord injuries, and other neurological disorders. The market for neurological disorder treatments is substantial, with an estimated global value of over $100 billion.